speaker-icon

Latest Posts

Partex-EDCC-collaboration-illustration

3

Jun 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

featured, Press release 2024
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More
Partex-Lupin-press-release-illustration

23

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

featured, Press release 2024
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Partex-Sanofi-press-release-illustration

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi’s out-licensing portfolio.

Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion of an innovative approach which leverages Partex’s AI arm, Innoplexus, and its proprietary AI technology to identify new indications within Sanofi’s out-licensing portfolio. Through meticulous indication expansion, prioritization, and lab validation studies, the collaboration endeavours to uncover fresh prospects for Sanofi’s out-licensing portfolio.

As a crucial component of this collaboration, Innoplexus will embark on a journey to scan, analyse, and enrich multiple out-licensing asset candidates, spanning therapeutic areas. The overarching vision is to explore avenues for repurposing or repositioning these assets for out-licensing focusing on patients’ needs.

Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative milestone collaboration, stating, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery. By harnessing the power of AI, we aspire to unlock the hidden potential within Sanofi’s out-licensing portfolio and bring hope to patients suffering from unmet medical needs. This collaboration is a testament to our shared commitment to advancing healthcare through cutting-edge technology.”

The collaboration is already in motion, with the selection of the first three assets for AI predictions, set to be completed in 2024.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing anavex_partex_partnership_Innoplexus
on June 27, 2023

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…

Read More